首页 > 最新文献

Precision Clinical Medicine最新文献

英文 中文
Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular? 个体化医疗方法能否有助于控制结核病,特别是在印度?
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-06-04 DOI: 10.1093/pcmedi/pbaa021
Nikhat Khan, Aparup Das
Abstract Poor drug compliance and drug-resistant Mycobacterium tuberculosis are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the N-acetyl transferase-2–isoniazid (NAT2–INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.
药物依从性差和耐药结核分枝杆菌是包括印度在内的结核病流行地区控制结核病(TB)的两大主要障碍,印度是全球结核病负担最大的国家。我们在这里认为,从n -乙酰转移酶-2 -异烟肼(NAT2-INH)模型开始的个性化医疗方法可能是解决印度控制结核病的这两个限制的一个进步。
{"title":"Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?","authors":"Nikhat Khan, Aparup Das","doi":"10.1093/pcmedi/pbaa021","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa021","url":null,"abstract":"Abstract Poor drug compliance and drug-resistant Mycobacterium tuberculosis are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the N-acetyl transferase-2–isoniazid (NAT2–INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"39 1","pages":"240 - 243"},"PeriodicalIF":5.3,"publicationDate":"2020-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86229615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions. 宏基因组引导干预改善肠易激综合征胃肠道健康
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-06-01 Epub Date: 2020-04-29 DOI: 10.1093/pcmedi/pbaa013
Cem Meydan, Ebrahim Afshinnekoo, Nate Rickard, Guy Daniels, Laura Kunces, Theresa Hardy, Loukia Lili, Sarah Pesce, Paul Jacobson, Christopher E Mason, Joel Dudley, Bodi Zhang

Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal disorder worldwide, and the most common reason for referral to gastroenterology clinics. However, the pathophysiology is still not fully understood and consequently current management guidelines are very symptom-specific, leading to mixed results. Here we present a study of 88 individuals with IBS who had baseline sequencing of their gut microbiome (stool samples), received targeted interventions that included dietary, supplement, prebiotic/probiotic, and lifestyle recommendations for a 30-day period, and a follow-up sequencing of their gut microbiome. The study's objectives were to demonstrate unique metagenomic signatures across the IBS phenotypes and to validate whether metagenomic-guided interventions could lead to improvement of symptom scores in individuals with IBS. Enrolled subjects also completed a baseline and post-intervention questionnaire that assessed their symptom scores. The average symptom score of an individual with IBS at baseline was 160 and at the endpoint of the study the average symptom score of the cohort was 100.9. The mixed IBS subtype showed the most significant reduction in symptom scores across the different subtypes (average decrease by 102 points, P = 0.005). The metagenomics analysis reveals shifts in the microbiome post-intervention that have been cross-validated with the literature as being associated with improvement of IBS symptoms. Given the complex nature of IBS, further studies with larger sample sizes, more targeted analyses, and a broader population cohort are needed to explore these results further.

肠易激综合征(IBS)是世界范围内最常见的功能性胃肠道疾病,也是转介到胃肠病学诊所的最常见原因。然而,病理生理学仍未完全了解,因此目前的治疗指南是非常具体的症状,导致混合的结果。在这里,我们提出了一项对88名肠易激综合征患者的研究,他们的肠道微生物组(粪便样本)进行了基线测序,接受了有针对性的干预,包括30天的饮食、补充剂、益生元/益生菌和生活方式建议,并对他们的肠道微生物组进行了后续测序。该研究的目的是在IBS表型中展示独特的宏基因组特征,并验证宏基因组引导的干预是否可以改善IBS患者的症状评分。入选的受试者还完成了基线和干预后问卷,以评估他们的症状评分。IBS患者在基线时的平均症状得分为160分,在研究结束时,该队列的平均症状得分为100.9分。混合IBS亚型在不同亚型的症状得分下降最为显著(平均下降102分,P = 0.005)。宏基因组学分析揭示了干预后微生物组的变化,这与文献交叉验证与IBS症状的改善有关。鉴于肠易激综合征的复杂性,进一步的研究需要更大的样本量、更有针对性的分析和更广泛的人群队列来进一步探索这些结果。
{"title":"Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions.","authors":"Cem Meydan,&nbsp;Ebrahim Afshinnekoo,&nbsp;Nate Rickard,&nbsp;Guy Daniels,&nbsp;Laura Kunces,&nbsp;Theresa Hardy,&nbsp;Loukia Lili,&nbsp;Sarah Pesce,&nbsp;Paul Jacobson,&nbsp;Christopher E Mason,&nbsp;Joel Dudley,&nbsp;Bodi Zhang","doi":"10.1093/pcmedi/pbaa013","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa013","url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal disorder worldwide, and the most common reason for referral to gastroenterology clinics. However, the pathophysiology is still not fully understood and consequently current management guidelines are very symptom-specific, leading to mixed results. Here we present a study of 88 individuals with IBS who had baseline sequencing of their gut microbiome (stool samples), received targeted interventions that included dietary, supplement, prebiotic/probiotic, and lifestyle recommendations for a 30-day period, and a follow-up sequencing of their gut microbiome. The study's objectives were to demonstrate unique metagenomic signatures across the IBS phenotypes and to validate whether metagenomic-guided interventions could lead to improvement of symptom scores in individuals with IBS. Enrolled subjects also completed a baseline and post-intervention questionnaire that assessed their symptom scores. The average symptom score of an individual with IBS at baseline was 160 and at the endpoint of the study the average symptom score of the cohort was 100.9. The mixed IBS subtype showed the most significant reduction in symptom scores across the different subtypes (average decrease by 102 points, <i>P</i> = 0.005). The metagenomics analysis reveals shifts in the microbiome post-intervention that have been cross-validated with the literature as being associated with improvement of IBS symptoms. Given the complex nature of IBS, further studies with larger sample sizes, more targeted analyses, and a broader population cohort are needed to explore these results further.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"3 2","pages":"136-146"},"PeriodicalIF":5.3,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/pcmedi/pbaa013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38170632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Double contrast-enhanced ultrasonography of a small intestinal neuroendocrine tumor: a case report of a recommendable imaging modality 小肠神经内分泌肿瘤的双重超声造影:推荐的成像方式1例报告
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-04-17 DOI: 10.1093/pcmedi/pbaa011
Jie-ying Zhao, H. Zhuang, Yuan Luo, M. Su, M. Xiong, Yu-ting Wu
Abstract A 57-year-old male presenting with spontaneously relieved abdominal cramp and distension was admitted to the West China Hospital. The diagnosis remained unclear after colonoscopy and computed tomography. Double contrast-enhanced ultrasonography was then performed and a neoplasm in the small intestine was suspected, supported by a thin-section computed tomography and positron emission tomography/computed tomography. This was confirmed pathologically after surgery to be a small intestinal G1 neuroendocrine tumor. Surgery was performed to remove approximately 25 cm of small bowel and a 3-cm solid mass located in the mesentery. The patient had a complete recovery and was tumor-free at the final follow-up. Small intestinal tumors including neuroendocrine tumors have always posed a diagnostic challenge. This case indicated that double contrast-enhanced ultrasonography is feasible in detection of small intestinal neuroendocrine tumors, and it may be an advisable approach assisting diagnosis of small intestinal tumors.
摘要一例57岁男性患者以腹部痉挛和腹胀自行缓解为主诉,住进华西医院。结肠镜检查和计算机断层扫描后诊断仍不清楚。然后行双超声增强检查,怀疑小肠肿瘤,并辅以薄层计算机断层扫描和正电子发射断层扫描/计算机断层扫描。术后病理证实为小肠G1神经内分泌肿瘤。手术切除约25厘米的小肠和位于肠系膜的3厘米的固体肿块。在最后的随访中,患者完全康复,无肿瘤。小肠肿瘤包括神经内分泌肿瘤一直是一个诊断难题。本病例提示超声双对比增强检查小肠神经内分泌肿瘤是可行的,可能是辅助小肠肿瘤诊断的一种可行方法。
{"title":"Double contrast-enhanced ultrasonography of a small intestinal neuroendocrine tumor: a case report of a recommendable imaging modality","authors":"Jie-ying Zhao, H. Zhuang, Yuan Luo, M. Su, M. Xiong, Yu-ting Wu","doi":"10.1093/pcmedi/pbaa011","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa011","url":null,"abstract":"Abstract A 57-year-old male presenting with spontaneously relieved abdominal cramp and distension was admitted to the West China Hospital. The diagnosis remained unclear after colonoscopy and computed tomography. Double contrast-enhanced ultrasonography was then performed and a neoplasm in the small intestine was suspected, supported by a thin-section computed tomography and positron emission tomography/computed tomography. This was confirmed pathologically after surgery to be a small intestinal G1 neuroendocrine tumor. Surgery was performed to remove approximately 25 cm of small bowel and a 3-cm solid mass located in the mesentery. The patient had a complete recovery and was tumor-free at the final follow-up. Small intestinal tumors including neuroendocrine tumors have always posed a diagnostic challenge. This case indicated that double contrast-enhanced ultrasonography is feasible in detection of small intestinal neuroendocrine tumors, and it may be an advisable approach assisting diagnosis of small intestinal tumors.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"89 1","pages":"147 - 152"},"PeriodicalIF":5.3,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90510021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA-based therapies in animal models of Leber congenital amaurosis causing blindness Leber先天性黑朦致盲动物模型的rna治疗
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-03-12 DOI: 10.1093/pcmedi/pbaa009
Xia Wang, Xianghong Shan, K. Gregory-Evans, C. Gregory-Evans
Abstract Leber congenital amaurosis (LCA) is a severe, genetically heterogeneous recessive eye disease in which ~ 35% of gene mutations are in-frame nonsense mutations coding for loss-of-function premature termination codons (PTCs) in mRNA. Nonsense suppression therapy allows read-through of PTCs leading to production of full-length protein. A limitation of nonsense suppression is that nonsense-mediated decay (NMD) degrades PTC-containing RNA transcripts. The purpose of this study was to determine whether inhibition of NMD could improve nonsense suppression efficacy in vivo. Using a high-throughput approach in the recessive cep290 zebrafish model of LCA (cep290;Q1223X), we first tested the NMD inhibitor Amlexanox in combination with the nonsense suppression drug Ataluren. We observed reduced retinal cell death and improved visual function. With these positive data, we next investigated whether this strategy was also applicable across species in two mammalian models: Rd12 (rpe65;R44X) and Rd3 (rd3;R107X) mouse models of LCA. In the Rd12 model, cell death was reduced, RPE65 protein was produced, and in vivo visual function testing was improved. We establish for the first time that the mechanism of action of Amlexanox in Rd12 retina was through reduced UPF1 phosphorylation. In the Rd3 model, however, no beneficial effect was observed with Ataluren alone or in combination with Amlexanox. This variation in response establishes that some forms of nonsense mutation LCA can be targeted by RNA therapies, but that this needs to be verified for each genotype. The implementation of precision medicine by identifying better responders to specific drugs is essential for development of validated retinal therapies.
Leber先天性黑内障(Leber congenital amaurosis, LCA)是一种严重的遗传异质性隐性眼病,其中约35%的基因突变是编码mRNA中功能缺失过早终止密码子(ptc)的框内无义突变。无义抑制疗法允许ptc的读取,从而产生全长蛋白。无义抑制的一个限制是无义介导的衰变(NMD)降解含有ptc的RNA转录物。本研究的目的是确定抑制NMD是否可以提高体内无义抑制的效果。采用高通量方法,在隐性cep290斑马鱼LCA模型(cep290;Q1223X)中,我们首先测试了NMD抑制剂Amlexanox与无糖抑制药物Ataluren联合使用。我们观察到视网膜细胞死亡减少,视觉功能改善。有了这些阳性数据,我们下一步研究了该策略是否也适用于两种哺乳动物模型:Rd12 (rpe65;R44X)和Rd3 (Rd3;R107X) LCA小鼠模型。在Rd12模型中,细胞死亡减少,RPE65蛋白产生,并改善了体内视觉功能测试。我们首次确定Amlexanox在Rd12视网膜中的作用机制是通过降低UPF1磷酸化。然而,在Rd3模型中,没有观察到阿塔鲁伦单独使用或与氨lexanox联合使用的有益效果。这种反应的变化表明,RNA疗法可以靶向某些形式的无义突变LCA,但这需要对每种基因型进行验证。通过确定对特定药物有更好反应的精准医学的实施对于开发有效的视网膜疗法至关重要。
{"title":"RNA-based therapies in animal models of Leber congenital amaurosis causing blindness","authors":"Xia Wang, Xianghong Shan, K. Gregory-Evans, C. Gregory-Evans","doi":"10.1093/pcmedi/pbaa009","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa009","url":null,"abstract":"Abstract Leber congenital amaurosis (LCA) is a severe, genetically heterogeneous recessive eye disease in which ~ 35% of gene mutations are in-frame nonsense mutations coding for loss-of-function premature termination codons (PTCs) in mRNA. Nonsense suppression therapy allows read-through of PTCs leading to production of full-length protein. A limitation of nonsense suppression is that nonsense-mediated decay (NMD) degrades PTC-containing RNA transcripts. The purpose of this study was to determine whether inhibition of NMD could improve nonsense suppression efficacy in vivo. Using a high-throughput approach in the recessive cep290 zebrafish model of LCA (cep290;Q1223X), we first tested the NMD inhibitor Amlexanox in combination with the nonsense suppression drug Ataluren. We observed reduced retinal cell death and improved visual function. With these positive data, we next investigated whether this strategy was also applicable across species in two mammalian models: Rd12 (rpe65;R44X) and Rd3 (rd3;R107X) mouse models of LCA. In the Rd12 model, cell death was reduced, RPE65 protein was produced, and in vivo visual function testing was improved. We establish for the first time that the mechanism of action of Amlexanox in Rd12 retina was through reduced UPF1 phosphorylation. In the Rd3 model, however, no beneficial effect was observed with Ataluren alone or in combination with Amlexanox. This variation in response establishes that some forms of nonsense mutation LCA can be targeted by RNA therapies, but that this needs to be verified for each genotype. The implementation of precision medicine by identifying better responders to specific drugs is essential for development of validated retinal therapies.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"181 1","pages":"113 - 126"},"PeriodicalIF":5.3,"publicationDate":"2020-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74545740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical applications of exosome membrane proteins. 外泌体膜蛋白的临床应用。
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-03-01 Epub Date: 2020-02-24 DOI: 10.1093/pcmedi/pbaa007
Qian Hu, Hang Su, Juan Li, Christopher Lyon, Wenfu Tang, Meihua Wan, Tony Ye Hu

Extracellular vesicles (EVs) are small membranous particles that can mediate cell-to-cell communication and which are divided into at least three categories according to their subcellular origin and size: exosomes, microvesicles, and apoptotic bodies. Exosomes are the smallest (30-150 nm) of these EVs, and play an important role in EV-mediated cell-to-cell interactions, by transferring proteins, nucleic acids and, lipids from their parental cells to adjacent or distant cells to alter their phenotypes. Most exosome studies in the past two decades have focused on their nucleic acid composition and their transfer of mRNAs and microRNAs to neighboring cells. However, exosomes also carry specific membrane proteins that can identify the physiological and pathological states of their parental cells or indicate their preferential target cells or tissues. Exosome membrane protein expression can also be directly employed or modified to allow exosomes to serve as drug delivery systems and therapeutic platforms, including in targeted therapy approaches. This review will briefly summarize information on exosome membrane proteins components and their role in exosome-cell interactions, including proteins associated with specific cell-interactions and diseases, and the potential for using exosome membrane proteins in therapeutic targeting approaches.

细胞外囊泡(EVs)是一种可以介导细胞间通讯的小膜状颗粒,根据其亚细胞起源和大小可分为至少三类:外泌体、微囊泡和凋亡小体。外泌体是这些ev中最小的(30- 150nm),在ev介导的细胞间相互作用中发挥重要作用,通过将蛋白质、核酸和脂质从亲本细胞转移到邻近或远端细胞以改变其表型。在过去的二十年中,大多数外泌体的研究都集中在它们的核酸组成和mrna和microrna向邻近细胞的转移上。然而,外泌体也携带特定的膜蛋白,可以识别亲本细胞的生理和病理状态,或指示它们优先的靶细胞或组织。外泌体膜蛋白表达也可以直接利用或修饰,使外泌体作为药物传递系统和治疗平台,包括靶向治疗方法。本文将简要介绍外泌体膜蛋白成分及其在外泌体-细胞相互作用中的作用,包括与特定细胞相互作用和疾病相关的蛋白质,以及外泌体膜蛋白在靶向治疗方法中的应用潜力。
{"title":"Clinical applications of exosome membrane proteins.","authors":"Qian Hu,&nbsp;Hang Su,&nbsp;Juan Li,&nbsp;Christopher Lyon,&nbsp;Wenfu Tang,&nbsp;Meihua Wan,&nbsp;Tony Ye Hu","doi":"10.1093/pcmedi/pbaa007","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa007","url":null,"abstract":"<p><p>Extracellular vesicles (EVs) are small membranous particles that can mediate cell-to-cell communication and which are divided into at least three categories according to their subcellular origin and size: exosomes, microvesicles, and apoptotic bodies. Exosomes are the smallest (30-150 nm) of these EVs, and play an important role in EV-mediated cell-to-cell interactions, by transferring proteins, nucleic acids and, lipids from their parental cells to adjacent or distant cells to alter their phenotypes. Most exosome studies in the past two decades have focused on their nucleic acid composition and their transfer of mRNAs and microRNAs to neighboring cells. However, exosomes also carry specific membrane proteins that can identify the physiological and pathological states of their parental cells or indicate their preferential target cells or tissues. Exosome membrane protein expression can also be directly employed or modified to allow exosomes to serve as drug delivery systems and therapeutic platforms, including in targeted therapy approaches. This review will briefly summarize information on exosome membrane proteins components and their role in exosome-cell interactions, including proteins associated with specific cell-interactions and diseases, and the potential for using exosome membrane proteins in therapeutic targeting approaches.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"3 1","pages":"54-66"},"PeriodicalIF":5.3,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/pcmedi/pbaa007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 88
Potassium channels as potential drug targets for limb wound repair and regeneration. 钾通道作为肢体创伤修复和再生的潜在药物靶点。
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-03-01 Epub Date: 2019-12-30 DOI: 10.1093/pcmedi/pbz029
Wengeng Zhang, Pragnya Das, Sarah Kelangi, Marianna Bei

Background: Ion channels are a large family of transmembrane proteins, accessible by soluble membrane-impermeable molecules, and thus are targets for development of therapeutic drugs. Ion channels are the second most common target for existing drugs, after G protein-coupled receptors, and are expected to make a big impact on precision medicine in many different diseases including wound repair and regeneration. Research has shown that endogenous bioelectric signaling mediated by ion channels is critical in non-mammalian limb regeneration. However, the role of ion channels in regeneration of limbs in mammalian systems is not yet defined.

Methods: To explore the role of potassium channels in limb wound repair and regeneration, the hindlimbs of mouse embryos were amputated at E12.5 when the wound is expected to regenerate and E15.5 when the wound is not expected to regenerate, and gene expression of potassium channels was studied.

Results: Most of the potassium channels were downregulated, except for the potassium channel kcnj8 (Kir6.1) which was upregulated in E12.5 embryos after amputation.

Conclusion: This study provides a new mouse limb regeneration model and demonstrates that potassium channels are potential drug targets for limb wound healing and regeneration.

背景:离子通道是跨膜蛋白的一大家族,可被可溶的膜不渗透分子所接近,因此是开发治疗药物的靶点。离子通道是现有药物的第二大常见靶标,仅次于G蛋白偶联受体,预计将对包括伤口修复和再生在内的许多不同疾病的精准医疗产生重大影响。研究表明,离子通道介导的内源性生物电信号在非哺乳动物肢体再生中起着至关重要的作用。然而,离子通道在哺乳动物肢体再生中的作用尚未明确。方法:为探讨钾通道在肢体创面修复与再生中的作用,分别在创面有望再生时的E12.5和E15.5切除小鼠胚胎后肢,研究钾通道的基因表达。结果:除kcnj8 (Kir6.1)钾通道在E12.5胚胎截肢后上调外,其余钾通道均下调。结论:本研究提供了一种新的小鼠肢体再生模型,证明了钾通道是肢体伤口愈合和再生的潜在药物靶点。
{"title":"Potassium channels as potential drug targets for limb wound repair and regeneration.","authors":"Wengeng Zhang,&nbsp;Pragnya Das,&nbsp;Sarah Kelangi,&nbsp;Marianna Bei","doi":"10.1093/pcmedi/pbz029","DOIUrl":"https://doi.org/10.1093/pcmedi/pbz029","url":null,"abstract":"<p><strong>Background: </strong>Ion channels are a large family of transmembrane proteins, accessible by soluble membrane-impermeable molecules, and thus are targets for development of therapeutic drugs. Ion channels are the second most common target for existing drugs, after G protein-coupled receptors, and are expected to make a big impact on precision medicine in many different diseases including wound repair and regeneration. Research has shown that endogenous bioelectric signaling mediated by ion channels is critical in non-mammalian limb regeneration. However, the role of ion channels in regeneration of limbs in mammalian systems is not yet defined.</p><p><strong>Methods: </strong>To explore the role of potassium channels in limb wound repair and regeneration, the hindlimbs of mouse embryos were amputated at E12.5 when the wound is expected to regenerate and E15.5 when the wound is not expected to regenerate, and gene expression of potassium channels was studied.</p><p><strong>Results: </strong>Most of the potassium channels were downregulated, except for the potassium channel <i>kcnj8</i> (Kir6.1) which was upregulated in E12.5 embryos after amputation.</p><p><strong>Conclusion: </strong>This study provides a new mouse limb regeneration model and demonstrates that potassium channels are potential drug targets for limb wound healing and regeneration.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"3 1","pages":"22-33"},"PeriodicalIF":5.3,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/pcmedi/pbz029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37809955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Double negative T cells, a potential biomarker for systemic lupus erythematosus. 双阴性T细胞,系统性红斑狼疮的潜在生物标志物。
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-03-01 Epub Date: 2020-01-20 DOI: 10.1093/pcmedi/pbaa001
Jessy J Alexander, Alexander Jacob, Anthony Chang, Richard J Quigg, James N Jarvis

Systemic lupus erythematosus (SLE) is an autoimmune disease that is a challenge to diagnose and treat. There is an urgent need for biomarkers to help define organ involvement, and more effective therapies. A unique population of T cells, the CD3+CD4-CD8- (DNeg) cells, is significantly increased in lupus patients. Twenty-seven cases (53%) of pediatric SLE patients had elevated DNeg cells in their peripheral blood, which correlated with kidney function (R2  = 0.54). Significant infiltration of DNeg cells was observed in both adult and pediatric lupus kidneys by immunofluorescence. For the first time, this study provides direct evidence that DNeg cells facilitate kidney injury in preclinical 8-week-old MRL/lpr lupus mice. In lupus mice, the increase in DNeg cells tracked with worsening disease and correlated with kidney function (R2  = 0.85). Our results show that DNeg cells per se can cause kidney dysfunction, increase in number with increase in disease pathology, and could serve as a potential biomarker.

系统性红斑狼疮(SLE)是一种自身免疫性疾病,诊断和治疗具有挑战性。迫切需要生物标记物来帮助确定器官受累情况,以及更有效的治疗方法。一种独特的T细胞群,CD3+CD4-CD8- (DNeg)细胞,在狼疮患者中显著增加。27例(53%)小儿SLE患者外周血DNeg细胞升高,与肾功能相关(R2 = 0.54)。免疫荧光法在成人和儿童狼疮肾中观察到明显的DNeg细胞浸润。本研究首次提供了DNeg细胞促进临床前8周龄MRL/lpr狼疮小鼠肾损伤的直接证据。在狼疮小鼠中,DNeg细胞的增加随着疾病的恶化而增加,并与肾功能相关(R2 = 0.85)。我们的研究结果表明,DNeg细胞本身可引起肾功能障碍,其数量随疾病病理的增加而增加,可以作为潜在的生物标志物。
{"title":"Double negative T cells, a potential biomarker for systemic lupus erythematosus.","authors":"Jessy J Alexander,&nbsp;Alexander Jacob,&nbsp;Anthony Chang,&nbsp;Richard J Quigg,&nbsp;James N Jarvis","doi":"10.1093/pcmedi/pbaa001","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa001","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is an autoimmune disease that is a challenge to diagnose and treat. There is an urgent need for biomarkers to help define organ involvement, and more effective therapies. A unique population of T cells, the CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup> (DNeg) cells, is significantly increased in lupus patients. Twenty-seven cases (53%) of pediatric SLE patients had elevated DNeg cells in their peripheral blood, which correlated with kidney function (<i>R<sup>2</sup></i>  = 0.54). Significant infiltration of DNeg cells was observed in both adult and pediatric lupus kidneys by immunofluorescence. For the first time, this study provides direct evidence that DNeg cells facilitate kidney injury in preclinical 8-week-old MRL/<i>lpr</i> lupus mice. In lupus mice, the increase in DNeg cells tracked with worsening disease and correlated with kidney function (<i>R<sup>2</sup></i>  = 0.85). Our results show that DNeg cells <i>per se</i> can cause kidney dysfunction, increase in number with increase in disease pathology, and could serve as a potential biomarker.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"3 1","pages":"34-43"},"PeriodicalIF":5.3,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/pcmedi/pbaa001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer 阿帕替尼治疗不可切除的胃肠道间质瘤合并同步胃癌
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-02-18 DOI: 10.1093/pcmedi/pbaa005
Huanji Xu, Sheng Zhou, Q. Hu, D. Cao
Abstract Nearly one-fifth of patients diagnosed with gastrointestinal stromal tumors (GISTs) simultaneously experience a second primary tumor. In particular, coexistence of gastric GISTs and gastric cancer is relatively more common. However, the optimal treatment for advanced GIST with gastric cancer is largely unknown. We report a case of simultaneous occurrence of gastric GIST and gastric cancer that benefited from apatinib. After first-line imatinib and S-1 treatment for 6 months, the GIST and the gastric cancer both progressed. The patient was then treated with apatinib, exhibiting a partial response (PR) both in the GIST and the gastric cancer at 7 months, and continuous PR so far with well-controlled toxic effects of hypertension. Progression-free survival reached 10 months. In view of the relatively high incidence of advanced GIST with synchronous gastric cancer, therapy to simultaneously treat the two kinds of tumors is urgently needed. Apatinib provides promising and well-tolerated therapy for GISTs with synchronous gastric cancer refractory to chemotherapy combined with imatinib.
近五分之一的胃肠道间质瘤(gist)患者同时发生第二原发肿瘤。尤其是胃间质间质瘤与胃癌共存的情况相对更为常见。然而,晚期GIST合并胃癌的最佳治疗方法在很大程度上是未知的。我们报告一例同时发生的胃间质瘤和胃癌,受益于阿帕替尼。一线伊马替尼和S-1治疗6个月后,GIST和胃癌均进展。患者随后接受阿帕替尼治疗,在7个月时胃肠道间质瘤和胃癌均出现部分缓解(PR),并且到目前为止持续缓解,高血压的毒性作用得到了很好的控制。无进展生存期达到10个月。鉴于晚期GIST合并同步胃癌的发生率较高,迫切需要两种肿瘤同时治疗的治疗方法。阿帕替尼为化疗联合伊马替尼难治的gist伴同步胃癌提供了有希望且耐受性良好的治疗方法。
{"title":"Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer","authors":"Huanji Xu, Sheng Zhou, Q. Hu, D. Cao","doi":"10.1093/pcmedi/pbaa005","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa005","url":null,"abstract":"Abstract Nearly one-fifth of patients diagnosed with gastrointestinal stromal tumors (GISTs) simultaneously experience a second primary tumor. In particular, coexistence of gastric GISTs and gastric cancer is relatively more common. However, the optimal treatment for advanced GIST with gastric cancer is largely unknown. We report a case of simultaneous occurrence of gastric GIST and gastric cancer that benefited from apatinib. After first-line imatinib and S-1 treatment for 6 months, the GIST and the gastric cancer both progressed. The patient was then treated with apatinib, exhibiting a partial response (PR) both in the GIST and the gastric cancer at 7 months, and continuous PR so far with well-controlled toxic effects of hypertension. Progression-free survival reached 10 months. In view of the relatively high incidence of advanced GIST with synchronous gastric cancer, therapy to simultaneously treat the two kinds of tumors is urgently needed. Apatinib provides promising and well-tolerated therapy for GISTs with synchronous gastric cancer refractory to chemotherapy combined with imatinib.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"18 1","pages":"67 - 70"},"PeriodicalIF":5.3,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88547656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Benign lymph node microenvironment is associated with response to immunotherapy 良性淋巴结微环境与免疫治疗应答相关
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-02-12 DOI: 10.1093/pcmedi/pbaa003
Maria I Toki, Deepika Kumar, F. Ahmed, D. Rimm, Mina L. Xu
Abstract Introduction Benign lymph nodes have been considered the hubs of immune surveillance in cancer patients. The microenvironment of these lymphoid tissues can be immune suppressed, hence allowing for tumor progression. Understanding the spectrum of benign findings in bystander lymph nodes in immune checkpoint blockade therapy could prove to be key to understanding the mechanism and assessing treatment response. Methods Benign lymph nodes and spleen were evaluated from patients treated with immunotherapy who subsequently received postmortem examination. We used quantitative immunofluorescence (QIF) to assess tumor infiltrating lymphocytes (TIL) and macrophage marker expression and characterized activation status using a novel multiplexed QIF assay including CD3, GranzymeB, and Ki67. We performed immunohistochemistry to correlate results of QIF. Results Benign lymph nodes from non-responders to immunotherapy showed significantly higher expression of cytotoxic markers and proliferation index (Ki67) in T cells compared to responders. Higher expression of PD-L1 in macrophages was also observed. There was no significant difference in CD3+ expression, but higher levels of CD8+ T cells as well as CD20+ B cells were seen in lymph nodes of non-responders. No significant differences were seen between responder and non-responder splenic tissue. Findings were supported by traditional immunostaining methods. Conclusions While most studies in biomarkers for immunotherapy focus on tumor microenvironment, we show that benign lymph node microenvironment may predict response to immunotherapy. In responding patients, bystander lymph nodes appear to have been mobilized, resulting in reduced cytotoxic T cells. Conversely, patients whose disease progressed on immunotherapy demonstrate higher levels of macrophages that express increased PD-L1, and activated T cells not recruited to the tumor site.
良性淋巴结一直被认为是癌症患者免疫监测的枢纽。这些淋巴组织的微环境可以被免疫抑制,因此允许肿瘤进展。了解免疫检查点阻断治疗中旁观者淋巴结的良性发现谱可能是理解机制和评估治疗反应的关键。方法对经免疫治疗的患者进行尸检,对其淋巴结和脾脏进行检查。我们使用定量免疫荧光(QIF)来评估肿瘤浸润淋巴细胞(TIL)和巨噬细胞标志物的表达,并使用一种新型的多重QIF检测,包括CD3、GranzymeB和Ki67。我们进行免疫组织化学来关联QIF的结果。结果免疫治疗无应答者淋巴结T细胞细胞毒性标志物和增殖指数(Ki67)的表达明显高于应答者。巨噬细胞中PD-L1的表达也较高。两组间CD3+表达差异无统计学意义,但无应答者淋巴结中CD8+ T细胞和CD20+ B细胞的表达水平较高。有反应和无反应的脾组织之间无显著差异。结果得到传统免疫染色方法的支持。虽然大多数关于免疫治疗生物标志物的研究都集中在肿瘤微环境上,但我们发现良性淋巴结微环境可以预测免疫治疗的反应。在有反应的患者中,旁观者淋巴结似乎被动员起来,导致细胞毒性T细胞减少。相反,在免疫治疗中疾病进展的患者表现出更高水平的巨噬细胞,表达增加的PD-L1,激活的T细胞未被募集到肿瘤部位。
{"title":"Benign lymph node microenvironment is associated with response to immunotherapy","authors":"Maria I Toki, Deepika Kumar, F. Ahmed, D. Rimm, Mina L. Xu","doi":"10.1093/pcmedi/pbaa003","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa003","url":null,"abstract":"Abstract Introduction Benign lymph nodes have been considered the hubs of immune surveillance in cancer patients. The microenvironment of these lymphoid tissues can be immune suppressed, hence allowing for tumor progression. Understanding the spectrum of benign findings in bystander lymph nodes in immune checkpoint blockade therapy could prove to be key to understanding the mechanism and assessing treatment response. Methods Benign lymph nodes and spleen were evaluated from patients treated with immunotherapy who subsequently received postmortem examination. We used quantitative immunofluorescence (QIF) to assess tumor infiltrating lymphocytes (TIL) and macrophage marker expression and characterized activation status using a novel multiplexed QIF assay including CD3, GranzymeB, and Ki67. We performed immunohistochemistry to correlate results of QIF. Results Benign lymph nodes from non-responders to immunotherapy showed significantly higher expression of cytotoxic markers and proliferation index (Ki67) in T cells compared to responders. Higher expression of PD-L1 in macrophages was also observed. There was no significant difference in CD3+ expression, but higher levels of CD8+ T cells as well as CD20+ B cells were seen in lymph nodes of non-responders. No significant differences were seen between responder and non-responder splenic tissue. Findings were supported by traditional immunostaining methods. Conclusions While most studies in biomarkers for immunotherapy focus on tumor microenvironment, we show that benign lymph node microenvironment may predict response to immunotherapy. In responding patients, bystander lymph nodes appear to have been mobilized, resulting in reduced cytotoxic T cells. Conversely, patients whose disease progressed on immunotherapy demonstrate higher levels of macrophages that express increased PD-L1, and activated T cells not recruited to the tumor site.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"119 1","pages":"44 - 53"},"PeriodicalIF":5.3,"publicationDate":"2020-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86124052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
A precision medicine approach to managing 2019 novel coronavirus pneumonia. 2019年新型冠状病毒肺炎的精准医疗方法
IF 5.3 4区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2020-02-04 DOI: 10.1093/pcmedi/pbaa002
Minjin Wang, Yanbing Zhou, Zhiyong Zong, Zongan Liang, Yu Cao, Hong Tang, Bin Song, Zixing Huang, Yan Kang, Ping Feng, Binwu Ying, Weimin Li

In December 2019, several patients with pneumonia of an unknown cause were detected in Wuhan, China. On 7 January 2020, the causal organism was identified as a new coronavirus, later named as the 2019 novel coronavirus (2019-nCoV). Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus. As of 29 January 2020, the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries. It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact. This finding has caused a great concern about the prevention of illness spread. The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections, making it difficult to diagnose. Given that the virus has a strong ability to spread between individuals, it is of top priority to identify potential or suspected patients as soon as possible-or the virus may cause a serious pandemic. Therefore, a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus. In this article, we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu, China.

2019年12月,中国武汉发现多例不明原因肺炎患者。2020年1月7日,病原生物被确定为一种新的冠状病毒,后来被命名为2019年新型冠状病毒(2019- ncov)。基因组测序发现,新型冠状病毒基因序列与严重急性呼吸综合征相关冠状病毒基因序列同源。截至2020年1月29日,中国有7000多名患者被确诊,其他国家有77名患者被确诊。据报道,新型冠状病毒有症状和无症状的患者均可通过空气传播和接触传播。这一发现引起了人们对预防疾病传播的极大关注。该感染的临床特征不明确,通常与其他呼吸道感染难以区分,因此难以诊断。鉴于该病毒具有很强的个体间传播能力,当务之急是尽快识别潜在或疑似患者,否则该病毒可能导致严重的大流行。因此,迫切需要一种精确的医学方法来管理这种疾病,以发现和控制病毒的传播。在本文中,我们根据最近发现的新型冠状病毒的独特特征和我们在中国成都华西医院处理冠状病毒的经验,提出了这样一种管理新型冠状病毒相关肺炎的方法。
{"title":"A precision medicine approach to managing 2019 novel coronavirus pneumonia.","authors":"Minjin Wang,&nbsp;Yanbing Zhou,&nbsp;Zhiyong Zong,&nbsp;Zongan Liang,&nbsp;Yu Cao,&nbsp;Hong Tang,&nbsp;Bin Song,&nbsp;Zixing Huang,&nbsp;Yan Kang,&nbsp;Ping Feng,&nbsp;Binwu Ying,&nbsp;Weimin Li","doi":"10.1093/pcmedi/pbaa002","DOIUrl":"https://doi.org/10.1093/pcmedi/pbaa002","url":null,"abstract":"<p><p>In December 2019, several patients with pneumonia of an unknown cause were detected in Wuhan, China. On 7 January 2020, the causal organism was identified as a new coronavirus, later named as the 2019 novel coronavirus (2019-nCoV). Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus. As of 29 January 2020, the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries. It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact. This finding has caused a great concern about the prevention of illness spread. The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections, making it difficult to diagnose. Given that the virus has a strong ability to spread between individuals, it is of top priority to identify potential or suspected patients as soon as possible-or the virus may cause a serious pandemic. Therefore, a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus. In this article, we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu, China.</p>","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"3 1","pages":"14-21"},"PeriodicalIF":5.3,"publicationDate":"2020-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/pcmedi/pbaa002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37868584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 50
期刊
Precision Clinical Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1